Invenra

This week’s episode of WisBusiness.com: the ??Podcast is with Roland Green, CEO of Madison-based Invenra. The pharmaceutical #biotechnology company earlier this year announced the U.S. FDA has approved special designations for its rare #pediatric #cancer treatment. These designations are meant to incentivize the drug’s development due to the impact it could have on affected patients. “We focus on developing antibody therapeutic drugs for a variety of diseases,” Green said. “#Oncology, #immunology, we’re starting to move into #radiotherapy. So it’s basically using nature’s approach to fighting the bad guys.” The FDA’s Rare Pediatric Disease and Orphan Drug Designations were announced in late August for Invenra’s #INV724 antibody product, which is meant for patients with a form of cancer called #neuroblastoma. It was created through a longstanding collaboration with Dr. Paul Sondel, a pediatric oncologist and researcher at University of Wisconsin-Madison. Listen at https://lnkd.in/gcf4gfra

???Exciting News! Invenra welcomes three industry leaders to our Board of Directors: Saira Gonsalves Ramasastry, Heather Preston, and William Hinshaw. These distinguished professionals bring decades of expertise in life sciences, biotherapeutic development and commercialization, and strategic growth. Their insights will be invaluable as we advance our mission to deliver groundbreaking bispecific antibody-based therapeutics. ? Join us in celebrating this milestone as we continue to innovate in the biotechnology field! #Invenra #Biotechnology #LifeSciences #BoardOfDirectors #BiotechNews??#AntibodyTherapeutics #BiotechInnovation #Leadership

We're excited to announce that Invenra has achieved another significant milestone: the U.S. FDA has granted INV724, our GD2 x B7-H3 bispecific antibody, an Orphan Drug Designation alongside our Rare Pediatric Disease Designation for the treatment of neuroblastoma. This dual recognition reinforces our unwavering commitment to advancing therapies for childhood cancer. ? https://lnkd.in/g_Er7nbe ? hashtag#Neuroblastoma?hashtag#RPDD?hashtag#ChildhoodCancerAwareness?hashtag#OncologyInnovationhashtag#RareDiseaseResearch?hashtag#PediatricOncology?hashtag#PatientAdvocacy?hashtag#FutureofHealthcare hashtag#endchildhoodcancer ?

https://lnkd.in/eEsVTiUv

We are thrilled to announce our strategic research agreement with Invenra, an innovative leader in bispecific antibody technology. This collaboration is a significant step toward advancing our focused research and development initiatives in bispecific therapeutic discovery. Under this agreement, we will have access to Invenra’s B-Body technology, allowing us to drive forward with our commitment to developing innovative and effective treatments for patients in need.? We are excited by the potential of this partnership and look forward to the possibilities it presents for the future of healthcare. Read more:? https://lnkd.in/gaVNUVRv #TherapeuticDiscovery #BispecificAntibody #HealthcareInnovation

A very big thank you to the members of both teams that helped put this collaboration between Invenra and Astellas Pharma in place. We are excited to let the science begin.

???Exciting News!??? ? We are pleased to announce a strategic research agreement with Astellas Pharma.? ? By joining forces, we're leveraging Invenra's state-of-the-art bispecific antibody platform to enhance Astellas' robust research and development capabilities. This strategic agreement aims to accelerate Astellas’ pursuit of groundbreaking therapies that promise a brighter future for patients worldwide. ? Follow Invenra’s journey as we innovate and transform the landscape of therapy solutions with our collaborators! ? #Invenra #Astellas #StrategicCollaboration #BispecificAntibodyPlatform #NextGenTherapeutics #InnovationforPatients #ScientificBreakthroughs #Biotechnology #Pharmaceuticals #PartnershipForHealth https://lnkd.in/gHhEfHP5

We can't wait to work with Catalent and co-discover novel bispecific ADCs.

We are excited to announce a strategic collaboration to leverage Invenra's B-Body Bispecific Platform and Catalent's SMARTag ADC expertise to generate innovative new cancer therapies. https://lnkd.in/gdmY_H4d

We're excited to announce a significant milestone for Invenra: the U.S. FDA has granted INV724, our GD2 x B7-H3 bispecific antibody, the Rare Pediatric Disease Designation for neuroblastoma treatment. This recognition underscores our commitment to advancing childhood cancer care. #Neuroblastoma #RPDD #ChildhoodCancerAwareness #OncologyInnovation #RareDiseaseResearch #PediatricOncology #PatientAdvocacy #FutureofHealthcare